Increased platelet activation and inflammatory response in patients with masked hypertension

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 2, 2013, Pages 170-174

  Guven, Aytekin ^a   Caliskan, Mustafa ^b   Ciftci, Ozgur ^a   Barutcu, Irfan ^c  

^a BASKENT UNIVERSITY   (Turkey)

^b KONYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Avicenna Hospital   (Turkey)

Author keywords

C reactive protein; essential hypertension; masked hypertension; mean platelet volume

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; MEAN PLATELET VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME;

ADULT; BLOOD PLATELETS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; MALE; MASKED HYPERTENSION; MIDDLE AGED; PLATELET ACTIVATION; RISK FACTORS;

EID: 84873356098     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835aba36     Document Type: Article

References (34)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-2494
2. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103:2096-2104
3. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115:3378-3384
4. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48:1083-1087
5. Kamath S, Blann AD, Lip GY. Platelet activation: Assessment and quantification. Eur Heart J 2001; 22:1561-1571
6. Hekimsoy Z, Payzin B, Ornek T, Kandogan G. Mean platelet volume in type 2 diabetic patients. J Diabetes Complications 2004; 18:173-176
7. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44:415-422
8. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 2001; 12:292-297
9. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992; 14:281-287
10. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59:981-982
11. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951
12. Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: Findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53:95-102
13. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403
14. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertensioñJ Hypertens 2001; 19:857-861
15. Engstrom G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgarde F. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22:2054-2058
16. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16:429-433
17. Wing LM, Brown MA, Beilin LJ, Ryan P, Reid CM, ANBP2 Management Committee and Investigators. Second Autralian National Blood Pressure Study. 'Reverse white-coat hypertension' in older hypertensives. J Hypertens 2002; 20:639-644
18. Pickering T, Davidson K, Gerin W, Schwartz GE. Masked hypertension. Hypertension 2002; 40:795-796
19. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46:508-515
20. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994; 24: 69-72
21. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338:1409-1411
22. Burr ML, Holliday RM, Fehily AM, Whitehead PJ. Haematological prognostic indices after myocardial infarction: Evidence from the diet and reinfarction trial (DART). Eur Heart J 1992; 13:166-170
23. Yang A, Pizzulli L, Lüderitz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 2006; 117:371-377
24. Giles C, Inglis TC. Thrombocytopenia and macrothrombocytosis in gestational hypertension. Br J Obstet Gynaecol 1981; 88:1115-1119
25. Coban E, Yazicioglu G, Avci AB, Akcit F. The mean platelet volume in patients with essential and white coat hypertension. Platelets 2005; 16:435-438
26. Varol E, Akcay S, Icli A, Yucel H, Ozkan E, Erdogan D, Ozaydin M. Mean platelet volume in patients with prehypertension and hypertension. Clin Hemorheol Microcirc 2010; 45:67-72
27. Kaya MG, Yarlioglues M, Gunebakmaz O, Gunturk E, Inanc T, Dogan A, et al. Platelet activation and inflammatory response in patients with nondipper hypertension. Atherosclerosis 2010; 209:278-282
28. Bath PM, Carney C, Markandu ND, MacGregor GA. Platelet volume is not increased in essential hypertension. J Hum Hypertens 1994; 8:457-459
29. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-Term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47:846-853
30. Delsart P, Marboeuf P, Delhaye C, Lemesle G, Mounier-Vehier C. Should we screen for masked hypertension in patient with vascular diseasëVasc Health Risk Manag 2010; 6:333-338
31. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44:6-11
32. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al. Increased C-reactive protein concentrations in never-Treated hypertension: The role of systolic and pulse pressures. J Hypertens 2003; 21:1841-1846
33. Niu K, Hozawa A, Fujita K, Ohmori K, Okutsu M, Kuriyama S, et al. Influence of leisure-Time physical activity on the relationship between C-reactive protein and hypertension in a community-based elderly population of Japan: The Tsurugaya project. Hypertens Res 2005; 28:747-754
34. Andrikou I, Tsioufis C, Dimitriadis K, Syrseloudis D, Valenti P, Almiroudi M, et al. Similar levels of low-grade inflammation and arterial stiffness in masked and white-coat hypertension: Comparisons with sustained hypertension and normotension. Blood Press Monit 2011; 16:218-223